Unpredictable changes of selected miRNA in expression profile of HNSCC.
BACKGROUND
The necessity of prediction and treatment outcome improvement of HNSCC needs to find new biomarkers. miRNAs seem to be good candidate for that.


OBJECTIVE
Analysis of selected 5 miRNAs (let-7d, miR-18a, miR-21, miR-205 and miR-375) as potential biomarkers that allows to distinguish tumor and healthy tissue taken from HNSCC patients.


METHODS
Tumor and normal epithelial tissues were obtained from 75 HNSCC patients to analyze selected miRNAs.


RESULTS
Analysis indicated significant increase of miR-21 and miR-205 in tumor when compared with healthy tissue (p= 0.0069 and p= 0.0029, respectively). There was a significant correlation between let-7d and miR-18a. let-7d was down-regulated in 34.67% cases, miR-18a in 29.33%, miR-21 in 20%, miR-205 in 30.67% and miR-375 in 52% cases. At the same time over-expression of let-7d was detected in 18.67% cases, miR-18a in 22.67%, miR-21 in 48%, miR-205 in 41.33% and miR-375 in 52% cases. There was no correlation between miRNA expression and clinical data and the course of illness.


CONCLUSIONS
Our study indicated that miR-21 and miR-205 can be used to analyze the clarity of surgical margins and that concomitant changes in the expression of let-7 and miR-18a in tumor tissues might represent important future markers indicating the biology of HNSCC. These observations will help with developing personalization for HNSCC patients' treatment.
Laboratory of Cancer Genetics, Greater Poland Cancer Center, Poznan, Poland.
Katarzyna M
KM
Lamperska
European Center of Bioinformatics and Genomics (ECBaG), Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Piotr
P
Kozlowski
Laboratory of Cancer Genetics, Greater Poland Cancer Center, Poznan, Poland.|Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland.
Tomasz
T
Kolenda
Laboratory of Cancer Genetics, Greater Poland Cancer Center, Poznan, Poland.
Anna
A
Teresiak
Laboratory of Cancer Genetics, Greater Poland Cancer Center, Poznan, Poland.
Renata
R
Blizniak
Laboratory of Cancer Genetics, Greater Poland Cancer Center, Poznan, Poland.
Weronika
W
Przybyla
Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, USA.
Michal M
MM
Masternak
Department of Head and Neck Surgery, Greater Poland Cancer Center, Poznan, Poland.
Pawel
P
Golusinski
Department of Head and Neck Surgery, Greater Poland Cancer Center, Poznan, Poland.
Wojciech
W
Golusinski
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D016000:Cluster Analysis; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006258:Head and Neck Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D000077195:Squamous Cell Carcinoma of Head and Neck; D059467:Transcriptome
D014408:Biomarkers, Tumor; D035683:MicroRNAs
Cancer; HNSCC; biomarker; miRNA profile; qRT-PCR